Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.525
-0.005 (-0.20%)
Nov 21, 2024, 2:09 PM EST - Market open

Company Description

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.

Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.

Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Cardiff Oncology, Inc.
Cardiff Oncology logo
Country United States
Founded 1999
Industry Biotechnology
Sector Healthcare
Employees 32
CEO Mark Erlander

Contact Details

Address:
11055 Flintkote Avenue
San Diego, California 92121
United States
Phone 858 952 7570
Website cardiffoncology.com

Stock Details

Ticker Symbol CRDF
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001213037
CUSIP Number 14147L108
ISIN Number US14147L1089
Employer ID 27-2004382
SIC Code 2836

Key Executives

Name Position
Dr. Mark Erlander Ph.D. Chief Executive Officer and Director
James E. Levine Chief Financial Officer
Dr. Fairooz F. Kabbinavar FACP, M.D. Chief Medical Officer
Dr. Tod Smeal Ph.D. Chief Scientific Officer
Elizabeth Anderson Vice President of Finance and Administration
Brigitte Lindsay Senior Vice President of Finance
Charles Monahan R.Ph. Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 8-K Current Report
Nov 7, 2024 10-Q Quarterly Report
Oct 24, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 8, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Jul 1, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 20, 2024 8-K Current Report
Jun 17, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 3, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material